Devonian Health Group, Inc. (TSE:GSD) has released an update.
Devonian Health Group Inc. has reported a robust second quarter in 2024, highlighting a 400% increase in top-line growth, the elimination of long-term debt, and expansion of their patent portfolio. Significant progress was also made with their subsidiary Altius launching a generic treatment for GERD in Canada and advancing towards phase II/III clinical trials for Thykamine in pediatric atopic dermatitis. The company has further streamlined its shares system to attract a broader investor base and meet international stock exchange listing requirements.
For further insights into TSE:GSD stock, check out TipRanks’ Stock Analysis page.
